# High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

> **NCT05011383** · PHASE2 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 51 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** High dose testosterone

## Key facts

- **NCT ID:** NCT05011383
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05011383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05011383, "High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05011383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*